Nathalie Laarakker
Director/Board Member chez OXURION NV
Profil
Nathalie Laarakker is currently the Chief Financial Officer & Director at Intravacc BV since 2021.
She is also an Independent Non-Executive Director at Oxurion NV since 2023.
Previously, she held the position of Chief Financial Officer & Managing Director at Gadeta BV and Head-Finance at Merus NV.
Ms. Laarakker completed her undergraduate degree at the University of Amsterdam.
Postes actifs de Nathalie Laarakker
| Sociétés | Poste | Début |
|---|---|---|
| OXURION NV | Director/Board Member | 02/05/2023 |
| Intravacc BV | Director/Board Member | 01/01/2021 |
Anciens postes connus de Nathalie Laarakker
| Sociétés | Poste | Fin |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | - |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Corporate Officer/Principal | - |
Formation de Nathalie Laarakker
| University of Amsterdam | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OXURION NV | Health Technology |
| MERUS N.V. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
| Intravacc BV |
